I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why
Source: SeekingAlpha
2026-01-05 09:53:52 ET
On November 25, my first coverage of Novo Nordisk A/S ( NVO ) was published on Seeking Alpha. Responding to recent news that its long-shot potential Alzheimer’s indication for Wegovy did not materialize as hoped, I nevertheless initiated coverage with a Buy rating. I considered the news more “noise” than a fundamental thesis breaker and believed in any case that after 18 months of negative sentiment endured by the company, the bottom was (finally) in....
Read the full article on Seeking Alpha
For further details see:
I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why
Innovent Biologics Inc
NASDAQ: IVBXF
IVBXF Trading
-1.19% G/L:
$9.95 Last:
8,095 Volume:
$10 Open:
